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Abstract
Background: The early identification of patients with ANCA-associated vasculitis (AAV) who are at increased risk for
inferior clinical outcome at the time of diagnosis might help to optimize the immunosuppressive therapy. In this
study we wanted to determine the predictive value of simple clinical characteristics, which may be applicable for
early risk-stratification of patients with AAV.
Methods: We retrospectively analyzed the outcome of 101 consecutive patients with AAV receiving a protocolized
immunosuppressive therapy. Baseline Birmingham Vasculitis Activity Score (BVAS) and non-vasculitic comorbidities
were computed, then predictors of early (<90 days) and late (>90 days) mortality, infectious death, relapse and end
stage kidney disease (ESKD) were evaluated.
Results: The baseline comorbidity score independently predicted early mortality (HR 1.622, CI 1.006–2.614), and
showed association with infectious mortality (HR 2.056, CI 1.247–3.392). Patients with BVAS at or above median
(=21) had worse early mortality in univariable analysis (HR 3.57, CI 1.039–12.243) (p = 0.031), and had more frequent
relapses (p = 0.01) compared to patients with BVAS below median.
Conclusions: Assessing baseline comorbidities, beside clinical indices characterizing the severity and extension of
AAV, might help clinicians in risk-stratification of patients. Future prospective studies are needed to investigate
whether therapies based on risk-stratification could improve both short term and long term survival.
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Background
The outcome of ANCA-associated vasculitis (AAV) has
improved significantly since the introduction of im-
munosuppressive therapy. On the other hand, both the
disease and the cytotoxic treatment are associated with
considerable morbidity and mortality [1, 2]. Ideally, pa-
tients should receive a treatment specifically tailored to
the severity of their disease. Other factors, however, such as
age, the extent of organ involvement and also baseline co-
morbidities may influence the outcome [3–7]. Therefore, in
order to optimize the intensity of immunosuppression and
to optimize outcomes, these factors would be important to
consider when planning the treatment schedule of the indi-
vidual patient at the time of diagnosis.
The Birmingham Vasculitis Activity Score (BVAS) is a
reliable tool to estimate the severity and extent of the
disease [8]. However, studies investigating it’s predictive
value on survival reported conflicting results [9–13]. Be-
side the activity of AAV, patients may have comorbid
conditions, that may also have an impact on their sur-
vival. Comorbidity scores are useful clinical tools for
risk-stratification of patients with chronic disorders, and
the role of comorbid conditions has been emphasized in
the mortality of dialysis patients [14, 15]. Therefore, it
seems reasonable to include comorbidity assessment in
the initial risk-startification at the time of presentation
with AAV.
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The aim of our study was to determine if simple clin-
ical and laboratory characteristics, readily available at
the time of diagnosis would predict mortality in patients
with BVAS. We assessed BVAS, and utilized a simplified
score by computing the most important baseline non-
vasculitic comorbidities for risk-stratification of patients
with AAV.
Methods
All consecutive patients, diagnosed with AAV at our
nephrology center between January, 1998 and June, 2013
were considered for this study. One patient, who died
within the first month, and 3, who were lost to follow-
up were excluded. Last follow-up was the date of death
or the end of study (December 31, 2013). Patients who
survived longer than the 8 years of follow-up (n = 15)
were censored at that time.
The diagnosis of necrotizing small vessel vasculitis was
defined according to the criteria of Chapel Hill consensus
conference [16, 17], by clinical presentation compatible
with AAV, positive ANCA serology and/or kidney biopsy.
Histological result confirmed the presence of crescentic/
necrotizing glomerulonephritis in all but 10 subjects, in
whom renal biopsy was not performed either because of
life threatening condition or due to refusal by the patients.
All these 10 patients were ANCA positive. Estimated GFR
(eGFR) was computed with CKD-EPI equation [18], and
BVAS (version 3) was calculated by scoring symptoms in
9 organ systems (general, cutaneous, mucus membranes/
eyes, ENT, chest, cardiovascular, abdominal, renal, and
nervous system) at admission [8] (Evaluelogix software by
EPS Research Ltd). Baseline comorbidity score was
assessed by determining conditions that had been present
before the AAV, namely history of myocardial infarction,
congestive heart failure, peripheral vascular disease, cere-
brovascular disease, chronic pulmonary disease, peptic
ulcer disease, liver disease, diabetes or malignancy. Scores
were given 0 if no comorbidity, 1 if a single comorbidity, 2
if two or more comorbidities existed.
Patients received protocolized therapy during the entire
observational period: 500–1000 mg intravenous (iv) metly-
prednisolone (MP) for three consecutive days, followed by
1 mg/kg/day per os for one month, then daily 48 mg in the
second, 36 mg in the third, 24 mg in the fourth, 16 then
12 mg in the fifth, and 8 then 4 mg in the sixth months,
continued with the maintenance dose of 4 mg/day, and
10 mg/kg iv bolus cyclophosphamide monthly for six
months, repeated at months 9 and 12. For subjects older
than 65 years the dose of immunosuppressive medications
was decreased by 15%, and for older than 70 years by 20%,
but the CYC dose was not modified by the glomerular fil-
tration rate. In 92 patients five plasmapheresis sessions
were also performed. Eighty-six patients followed the
protocol strictly. When we analyzed their data separately,
the results were comparable to the findings in the whole
cohort. After twelve months azathioprine was introduced,
accompanied by 4 mg methylprednisolone given daily or
every other day as long-term maintenance therapy, at the
discretion of the attending nephrologist.
In case of relapse, the induction immunosuppressive
regime was repeated.
Remission was defined as disappearance of clinical dis-
ease activity and stabilization or improvement of the kidney
function. Resolution of hematuria was also criteria for re-
mission, but persistent proteinuria was considered as the
consequence of glomerular damage. In patients who
remained dialysis dependent we considered remission if the
extrarenal manifestations and the hematuria completely
ceased. Relapse was defined as recurrence of presenting
symptoms or appearance of a new organ involvement at-
tributable to AAV. Those, in whom remission could not be
achieved, who died due to active vasculitis, or had low
grade of persistent “grumbling disease” were considered as
treatment resistant patients.
The main exposure variables were the comorbidity
score (the sum of comorbidities at the time of admis-
sion) and the BVAS score (categorized as below or above
median [median = 21] score).
The primary end points were all cause early (<90 days)
and late (>90 days) mortality. Secondary end points con-
sisted of deaths due to infections, rate of relapse and
end stage kidney disease (ESKD).
Statistical analyses were performed using SPSS 20.0
(IBM, Chicago, IL) and STATA MP version 12 (Stata
Corporation, College Station, TX). Variables were re-
ported as mean (SD) or median and range, comparison
between groups was analyzed by Student’s t-tests,
Mann–Whitney U tests or χ2 tests, as appropriate. Mor-
tality risk was calculated by Kaplan-Meier method, and
log-rank tests to compare groups. Predictors of death
were evaluated separately for early (<90 days) and late
(>90 days) mortality.
Patients with BVAS below and at or above median
were compared. Although the relatively small number of
events limited multivariable analyses [19], for this pur-
pose those variables were selected, that were considered
important predictors of outcomes of AAV based on clin-
ical experience or the results of the univariable analyses.
Multivariable models were sequentially adjusted for
age, serum albumin, HD dependency on admission, and
ANCA type (negative, p- or c-ANCA). Serum CRP was
not used in the multivariable models due to the small
number of events and also because of its strong correl-
ation with serum albumin.
Logistic regression models were used to analyze the
association between exposure variables and relapse,
since we considered all relapses for these analyses and
we did not consider the time to events.
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Results are expressed as hazard ratios (HRs) with 95%
confidence intervals (CIs) and p values. All tests were
two-tailed, unadjusted for multiple comparisons, and p
values of < 0.05 were considered significant.
Results
Baseline data of the 101 individuals are presented in
Table 1. Subjects with BVAS at or above median (median
BVAS = 21) had lower Hgb (p = 0.017), more c-ANCA
positivity (p = 0.024), and needed HD on admission more
often (p = 0.012), compared to the individuals with BVAS
below median.
Treatment protocol was strictly followed with only few
exceptions, as excluded iv MP pulses in 1 and 2 patients
and excluded CYC boluses in 3 and 1 patients in the
BVAS at or above and below median groups, respect-
ively; CYC was administered orally in 2 patients in the
BVAS below median group. Subjects with BVAS at or
above median got higher dose of pulse MP (p = 0.002)
compared to the individuals with BVAS below median,
but the dose of CYC and the cumulative dose of MP did
not differ between the groups (Table 1).
The median survival in the study sample was 1877
(95%CI 753–2246) days. Mortality during the first year
was 33%. Nineteen patients died within the first 90 days
(“early mortality”), and 41 after the 90th day of follow-up
(“late mortality”). The cumulative probability of survival
was 0.441 (95%CI 0.231–0.633) versus 0.233 (95%CI
0.126–0.359) (p = 0.028) in patients with a BVAS score
below versus at or above median, respectively (Fig. 1).
The cumulative probability of early (within 90 days after
diagnosis) survival was also worse in patients with
higher BVAS: 0.921 (95%CI 0.775–0.974) versus 0.746
(95%CI 0.619–0.836) (p = 0.031). Early mortality was also
predicted by baseline comorbidity score, albumin, CRP
and HD requirement on admission in urivariable Cox
regression analysis (Table 2). In a multivariable model
adjusted for BVAS, age, serum albumin, ANCA type and
HD requirement on admission comorbidity score
remained a significant predictor for early mortality (HR
1.622, CI 1.006–2.614, p = 0.047) (Table 3).
Late (>90 days after diagnosis) mortality was predicted
by age, comorbidity score and HD requirement on ad-
mission in univariable analysis (Table 4). In the most
fully adjusted model adjusted for age, serum albumin,
HD dependency on admission and ANCA type, comor-
bidity was not a significant predictor any more. In this
model, however, BVAS independently predicted all cause
late mortality (HR 2.408, 95%CI 1.081–5.362, Table 5).
Seven patients died of infections (37%), 4 of cardiovas-
cular diseases (21%) and 7 of AAV activity (37%) within
the first 90 days. Late mortality occurred from infections
in 13 (32%), cardiovascular diseases in 12 (29%), active
AAV during relapse in 6 patients (15%). Reason for
death was unknown in 10 additional cases (1 early, 9 late
mortality), and late malignancy was responsible for one
death. The following types of infections were documented:
bacterial and fungal respiratory tract infections, pulmon-
ary abscess, cerebral abscess, sepsis, disseminated herpes
zoster. Both comorbidity and BVAS predicted infectious
mortality (HR 2.191, 95%CI 1.486–3.231; HR 3.792,
95%CI 1.111–12.949, respectively) in univariable models.
The predictive value of comorbidity and BVAS remained
significant after adjustment for age, serum albumin,
ANCA types, and HD dependency (HR 2.056, 95%CI
1.247–3.392; HR 5.079, 95%CI 1.396–18.480, respectively).
By induction immunosuppression remission was
achieved in all but one patient, who survived more than
90 days (81 patients, 80%). On the long term, ESKD de-
veloped in 3 patients who had not required dialysis at
diagnosis, but suffered renal failure likely due to low
grade persistent disease activity. Thirty-seven patients
remained dialysis dependent at study end. Serum cre-
atinine and eGFR in patients who were off dialysis at the
end of follow-up (n = 64) were 168 umol/l (83–434) and
33 ml/min (11–88), respectively. In those, who had
BVAS at or above median on admission, serum creatin-
ine at the end of follow-up was significantly higher (191
umol/l (88–418)), compared to patients with BVAS
below median (143 umol/l (83–434), p = 0.041). The
corresponding eGFR values were 26 and 38 ml/min
(11–75 and 12–88, p = 0.092, respectively). Frequency
of long term HD dependency in patients with BVAS at
or above and below median did not differ significantly.
Forty relapses occurred in 24 patients, 10 of them ex-
perienced 2–4 relapses. The proportion of patients with
relapses was 30% in the BVAS at or above median and
13% in the BVAS below median group (p = 0.052). There
was significant difference in the number of relapses
between the subgroups with BVAS at or above and
below median (34 relapses in 63 patients vs. 6 relapses
in 38 patients, p = 0.01). Although BVAS showed associ-
ation with relapse in univariable logistic regression
model (OR = 1.130 CI 1.028–1.243), after correcting for
the type of ANCA (c-ANCA versus p-ANCA), BVAS
was not a significant predictor of relapse any more.
Discussion
The main result of our analysis is that in AAV patients
with predominant renal and pulmonary involvement,
comorbidity score independently predicted short term
survival. It also proved to be a predictor of infectious mor-
tality. On protocolized immunosuppressive therapy, pa-
tients, who had high BVAS at baseline, had significantly
poorer short term survival and more frequent relapses
than subjects with lower than median score. When analyz-
ing early and late mortality separately, BVAS did not pre-
dict outcome in univariable analysis.
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Table 1 Demographics, baseline data and comorbidities at time of diagnosis (mean (SD) or median and range)
Variable All patients Patients
with BVAS ≥ 21
Patients
with BVAS < 21
p value
n of patients 101 63 38
Age (years) 61.4 (13) 60.2 (14) 63.3 (11) 0.237
Male/female 40/61 27/36 13/25 0.389
Time from first symptoms to diagnosis (months) 5.0 (1–36) 5.0 (1–24) 6.0 (1–36) 0.822
Hemoglobin (g%) 8.4 (1.4) 8.1 (1.3) 8.8 (1.5) 0.017
Erythrocyte sedimentation rate (mm/h) 98 (5–138) 98 (5–138) 99 (14–136) 0.762
Serum albumin (g/l) 31.3 (5.4) 30.8 (5.3) 32.0 (5.6) 0.285
CRP (mg/l) 29 (1–221) 40 (2–221) 24 (1–152) 0.054
Urinary protein excretion (mg/day) 1456 (38–8474) 1259 (38–8474) 1843 (184–7344) 0.143
Serum creatinine (umol/l) 554 (84–1904) 573 (146–1904) 428 (84–1722) 0.060
HD requirement on admission (n, %) 56 (55%) 41 (65%) 15 (40%) 0.012
BVAS 21 (11–34) 24 (21–34) 15 (11–20) <0.001
p-/c-ANCA positivity (n)* 57/36 33/29 24/7 0.024
Anti-MPO level in p-ANCA positive patients (IU/ml) 67 (6–100) 67 (6–100) 70 (11–100) 0.807
Anti-PR3 level in c-ANCA positive patients (IU/ml) 100 (32–100) 100 (50–100) 82 (32–100) 0.354
Dose of iv pulse MP** mg/kg/bw 11.7 (4.1) 12.7 (4.2) 10.1 (3.3) 0.002
Dose of iv bolus CYC*** mg/kg/bw 9.7 (1.6) 9.8 (1.6) 9.5 (1.6) 0.371
Cumulative dose of MP (mg) 11640 (3006–32334) 11238 (3006–32334) 12332 (5076–26364) 0.621
Follow-up time (days) 963 (30–3000) 843 (30–3000) 1393 (51–3000) 0.231
Organ involvement n (%)
Renal 101 (100) 63 (100) 38 (100) 1.000
Respiratory tract 43 (43) 38 (60) 5 (13) <0.001
Ear-throat-nose 39 (39) 33 (52) 6 (16) <0.001
Musculoskeletal 55 (55) 33 (52) 22 (58) 0.590
Skin 16 (16) 9 (14) 7 (18) 0.581
Eyes 5 (5) 4 (6) 1 (3) 0.648
Gastrointestinal 9 (9) 9 (14) 0 (0) 0.013
Nervous system 17 (17) 14 (22) 3 (8) 0.062
Cardiovascular 5 (5) 5 (8) 0 (0) 0.154
Baseline comorbidities n (%) 963 (30–3000) 843 (30–3000) 1393 (51–3000) 0.231
History of:
Coronary artery disease 11 (11) 9 (14) 2 (5) 0.201
Congestive heart failure 5 (5) 4 (6) 1 (3) 0.648
Peripheral vascular dis. 1 (1) 1 (2) 0 (0) 1.000
Cerebrovascular disease 11 (11) 7 (11) 4 (11) 1.000
Chronic pulmonary dis. 16 (16) 9 (14) 7 (18) 0.581
Peptic ulcer disease 8 (8) 6 (10) 2 (5) 0.707
Liver disease 5 (5) 4 (6) 1 (3) 0.648
Diabetes mellitus 8 (8) 3 (5) 5 (13) 0.149
Malignancy 7 (7) 3 (5) 4 (11) 0.421
Number of patients with
0 50 30 20 0.862
1 30 19 11
2 or more comorbidity scores 21 14 7
*Eight patients were ANCA negative, all of them had renal biopsy which proved the diagnosis of pauci-immune crescentic glomerulonephritis
**MP – methylprednisolone, administered for 98 patients
***CYC – cyclophosphamide, administered for 95 patients
Comorbidity scores were given 0 if no comorbidity, 1 if a single comorbidity, 2 if two or more comorbidities existed
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BVAS, originally designed to standardize disease as-
sessment in AAV, shows good correlation with clinical
activity of the disease [8]. Flossmann et al. documented,
that BVAS was a significant predictor of mortality by
analyzing the data of patients recruited for randomized
controlled trials. Patients in that study were somewhat
different from the ones enrolled in ours, since the me-
dian BVAS was lower, renal function was less severely
compromised, and subjects with life-threatening pul-
monary hemorrhage were excluded [1]. On the contrary,
predictive value of BVAS was not found in several other
investigations. Bakoush and coworkers followed 83 pa-
tients; neither survival nor ESKD was predicted by BVAS
in their cohort, with less severe renal failure compared
to our patients [9]. In Japanese patients with MPO-
ANCA disease, no association was found between BVAS
and mortality during the two years follow-up [20]. In an-
other investigation there was no difference between the
baseline BVAS of survivors and non-survivors; baseline
BVAS did not, but BVAS at 1 and 3 months predicted
survival [21].
The difference in the association between BVAS and out-
come in these cohorts and ours can be due to a variety of
factors. Event number, therefore statistical power, patient
selection, disease severity and treatment approach were
quite heterogeneous across these studies. It also seems im-
portant to differentiate early and late survival, as the hazard
of mortality is not proportional in these periods. We have
defined the timeframe of early death in 3 months, as risk of
severe complications of AAV, also intensity of immunosup-
pression are the highest during this period.
To our knowledge, only one study has investigated
the association between comorbidities and risk of all
cause death in AAV patients. Little et al. found, that
the Karnofsky performance score, but not the non-
vasculitic comorbidity showed independent association
with mortality [22]. Although we did not include Karnofsky
performance in our dataset, we found a significant as-
sociation of comorbidity and early mortality, and this
relationship remained independent of other important
clinical characteristics.
Fig. 1 Kaplan-Meier survival curves of patients with BVAS at or
above and below median in the entire observation period (p = 0.028,
log-rank test)
Table 2 Predictors of “early mortality” in univariable Cox regression
analysis
HR 95% CI P value
Age 1.035 0.994–1.078 0.097
Albumin 0.891 0.818–0.970 0.007
ANCA type – ANCA neg REF REF REF
pANCA 0.604 0.215–1.695 0.338
cANCA 0.516 0.067–3.945 0.524
BVAS median 3.57 1.039–12.243 0.043
CRP 1.011 1.003–1.018 0.005
Comorbidity score 1.707 1.176–2.477 0.005
HD on admission 3.404 1.130–20.260 0.030
Table 3 Comorbidity score predicts “early mortality” in
multivariable Cox regression analysis. Table shows the
parameters of the “comorbidity score” variable in different
models
HR 95% CI P value
Model 1 1.707 1.176–2.477 0.005
Model 2 1.752 1.225–2.506 0.002
Model 3 1.694 1.072–2.677 0.024
Model 4 1.622 1.006–2.614 0.047
Model 1: comorbidity score
Model 2: Model 1 + BVAS median
Model 3: Model 2 + Age, serum albumin
Model 4: Model 3 + HD dependency on admission and ANCA type
(c-versus p-ANCA)
Table 4 Predictors of “late mortality” in univariable Cox
regression analysis
HR 95% CI P value
Age 1.059 1.028–1.092 <0.001
Albumin 0.950 0.895–1.009 0.094
ANCA type – ANCA neg REF REF REF
pANCA 0.658 0.341–1.268 0.211
cANCA 0.674 0.159–2.853 0.592
BVAS median 1.483 0.768–2.865 0.241
CRP 0.999 0.993–1.007 0.993
Comorbidity score 1.526 1.106–2.106 0.010
HD on admission 2.157 1.131–4.116 0.020
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We did not find other investigations assessing the as-
sociation between comorbidities and infectious death.
Importantly, this reveals the complexity of treatment of
AAV patients: likely those without any comorbidity may
tolerate aggressive immunosuppression and AAV better,
compared to subjects suffering from various chronic
disorders. Remarkably, in another study, accumulation
of adverse events in the first year of treatment - which
influenced survival significantly – was independently as-
sociated with age and renal impairment [2]. Based on
these latter findings we propose, that not only age and
kidney function, but also the presence of non-vasculitic
comorbidities present high risk status for adverse events,
especially for infections, which may provide an explan-
ation for the increased mortality.
Our findings are in accord with several other reports
showing that the severity of kidney disease at baseline is
an indicator of poor prognosis [1, 6, 9, 10]. Similarly, high
levels of the inflammatory markers (CRP, albumin, etc.)
confer an increased early mortality risk for the individual
patient [5, 7]. The applicability of these predictors is
important, as these are readily available at the first presen-
tation of the patient.
The frequency of ESKD did not differ in the BVAS
groups in our cohort, similarly to other investigations
[4, 23]. We found more frequent relapses in patients
with higher BVAS; BVAS predicted relapse in Cox regres-
sion analysis, but the association was not significant after
adjustment for ANCA type. The likely explanation for this
observation is, that the higher BVAS in our cohort, com-
prising patients with both respiratory tract and kidney in-
volvement, was associated with c-ANCA disease, which
characteristically confers a higher risk of relapse compared
to p-ANCA positive vasculitis [24]. In comparison, in a
study investigating patients exclusively with c-ANCA posi-
tivity, relapses occurred more often in those who presented
with lower BVAS, compared to more severe cases [25]. A
possible explanation for this difference can be the different
case mix: cohorts with predominantly upper respiratory
tract involvement but no kidney disease have lower BVAS
but more relapses than those with renal AAV [26].
Our study has several limitations. Most importantly,
BVAS was calculated retrospectively. Nevertheless, detailed
source data provided reliable information, and the strictly
followed treatment protocol also assisted our analysis. Mor-
tality rate was fairly high, which likely can be explained by
very late referrals. This resulted in advanced renal failure
and extensive manifestations of AAV in most of our
patients. The extensive comorbidities might also have con-
tributed to the observed high mortality.
In conclusion, baseline comorbidities influence both
short and long term outcome of patients with AAV.
Risk-stratification would help clinicians to tailor therapy
individually, which might further improve the outcome.
Future prospective treatment studies are needed to
assess whether scoring systems based on comorbidities
and BVAS help to individualize therapies in order to im-
prove short and long term survival.
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Table 5 BVAS predicts “late mortality” in multivariable Cox
regression analysis. The table shows the parameters of the
“BVAS median” variable in the different models
HR 95% CI P value
Model 1 1.483 0.768–2.865 0.241
Model 2 2.073 1.030–2.435 0.041
Model 3 2.558 1.251–5.231 0.010
Model 4 2.408 1.081–5.362 0.031
Model 1: BVAS median
Model 2: Model 1 + comorbidity score
Model 3: Model 2 + Age, serum albumin
Model 4: Model 3 + HD dependency on admission and ANCA type (c-
versus p-ANCA)
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